Response after Surgical Resection of Metastatic Pheochromocytoma and Paraganglioma: Can Postoperative Biochemical Remission Be Predicted?

被引:31
作者
Ellis, Ryan J. [1 ,4 ]
Patel, Dhaval [1 ]
Prodanov, Tamara [3 ]
Sadowski, Samira [1 ]
Nilubol, Naris [1 ]
Adams, Karen [3 ]
Steinberg, Seth M. [2 ]
Pacak, Karel [3 ]
Kebebew, Electron [1 ]
机构
[1] NCI, Endocrine Oncol Branch, Bethesda, MD 20892 USA
[2] NCI, Biostat & Data Management Sect, Off Clin Director, Bethesda, MD 20892 USA
[3] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD USA
[4] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
关键词
MALIGNANT PHEOCHROMOCYTOMAS; SURVIVAL; SDHB;
D O I
10.1016/j.jamcollsurg.2013.04.027
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Aggressive surgical resection with intent to cure and surgical debulking procedures are commonly recommended in patients with metastatic pheochromocytoma and paraganglioma. To date there are no data on operative outcomes of patients after surgical resection of metastatic pheochromocytoma and paraganglioma to determine if such an approach is appropriate and what factors may be associated with a favorable outcome. STUDY DESIGN: We performed a retrospective analysis of 30 patients with metastatic pheochromocytoma/paraganglioma who underwent surgical treatment. Clinical characteristics and genetic factors were analyzed as predictors of biochemical response to surgery. RESULTS: Thirty patients underwent a total of 42 operations, with a median follow-up time of 24 months (range 1 to 114 months). Complete disease resection (R0/R1) was achieved in 18 (42.9%) cases; 24 cases (57.1%) were debulking (R2) procedures without intent to cure. Complete biochemical remission was achieved in 10 (23.8%) cases and partial biochemical response was achieved in 23 (54.8%) cases. Patients with disease confined to the abdomen were more likely to achieve and maintain a biochemical response postoperatively than those with extra-abdominal disease (p = 0.0003). Debulking operations were significantly less likely to achieve or maintain biochemical palliation, with only 1 patient maintaining a biochemical response 12 months postoperatively (p < 0.0001). Patients were less likely to obtain pharmacologic independence after debulking (p = 0.0003), with only 2 (8.3%) not requiring pharmacotherapy 6 months after the intervention. Factors not associated with biochemical response to surgery include sex, family history, SDHB mutation status, systemic therapy, and preoperative biochemical profile. CONCLUSIONS: Depending on the extent of disease, patients with metastatic pheochromocytoma/paraganglioma can benefit from aggressive operative intervention and resection with intent to cure. Debulking procedures are unlikely to achieve clinically significant biochemical response, with any biochemical response achieved being very short-lived. ((c) 2013 by the American College of Surgeons)
引用
收藏
页码:489 / 496
页数:8
相关论文
共 31 条
[1]   Treatment of Malignant Pheochromocytoma [J].
Adjalle, R. ;
Plouin, P. F. ;
Pacak, K. ;
Lehnert, H. .
HORMONE AND METABOLIC RESEARCH, 2009, 41 (09) :687-696
[2]   Cardiovascular dysfunction and catecholamine cardiomyopathy in pheochromocytoma patients and their reversal following surgical cure: Results of a prospective case-control study [J].
Agarwal, Gaurav ;
Sadacharan, Dhalapathy ;
Kapoor, Aditya ;
Batra, Aditya ;
Dabadghao, Preeti ;
Chand, Gyan ;
Mishra, Anjali ;
Agarwal, Amit ;
Verma, Ashok K. ;
Mishra, Saroj K. .
SURGERY, 2011, 150 (06) :1202-1210
[3]  
Agresti A., 1990, CATEGORICAL DATA ANA
[4]   Malignant pheochromocytoma - State of the field with future projections [J].
Ahlman, Hakan .
PHEOCHROMOCYTOMA, 2006, 1073 :449-464
[5]   Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas [J].
Amar, Laurence ;
Baudin, Eric ;
Burnichon, Nelly ;
Peyrard, Severine ;
Silvera, Stephane ;
Bertherat, Jerome ;
Bertagna, Xavier ;
Schlumberger, Martin ;
Jeunemaitre, Xavier ;
Gimenez-Roqueplo, Anne-Paule ;
Plouin, Pierre-Francois .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (10) :3822-3828
[6]   Changes in urinary total metanephrine excretion in recurrent and malignant pheochromocytomas and secreting paragangliomas [J].
Amar, Laurence ;
Peyrard, Severine ;
Rossignol, Patrick ;
Zinzindohoue, Franck ;
Gimenez-Roqueplo, Anne-Paule ;
Plouin, Pierre-Francois .
PHEOCHROMOCYTOMA, 2006, 1073 :383-391
[7]  
[Anonymous], 2004, WHO CLASSIFICATION T
[8]   Pheochromocytoma - An approach to antihypertensive management [J].
Bravo, EL .
ENDOCRINE HYPERTENSION, 2002, 970 :1-10
[9]   Understanding Catecholamine Metabolism as a Guide to the Biochemical Diagnosis of Pheochromocytoma [J].
Eisenhofer G. ;
Huynh T.-T. ;
Hiroi M. ;
Pacak K. .
Reviews in Endocrine and Metabolic Disorders, 2001, 2 (3) :297-311
[10]   Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status [J].
Eisenhofer, Graeme ;
Lenders, Jacques W. M. ;
Siegert, Gabriele ;
Bornstein, Stefan R. ;
Friberg, Peter ;
Milosevic, Dragana ;
Mannelli, Massimo ;
Linehan, W. Marston ;
Adams, Karen ;
Timmers, Henri J. ;
Pacak, Karel .
EUROPEAN JOURNAL OF CANCER, 2012, 48 (11) :1739-1749